Abstract
Background & aims Sex differences in non-alcoholic fatty liver disease (NAFLD) are well known and yet, most of the studies available in the literature do not include this factor when analysing the data. Here we present a functional meta-analysis of NAFLD studies to detect sex-related alterations of molecular mechanisms, between stages of the disease.
Methods We systematically reviewed the Gene Expression Omnibus database functional Gene Ontology terms detailed in transcriptomic studies, following the PRISMA statement guidelines. For each study, we compared steatosis (NAFL) and steatohepatitis (NASH), in premenopausal women and men using a dual strategy: a gene-set analysis and a pathway activity analysis. The functional results of all the studies were integrated in a meta-analysis.
Results A total of 114 abstracts were reviewed and 7 studies, which included 323 eligible patients, were finally analysed. The meta-analyses highlighted significant functions in both sexes. In premenopausal women, the overrepresented functions referred to DNA regulation, vinculin binding, IL-2 responses, negative regulation of neuronal death, and the transport of ions and cations. In men, they referred to the negative regulation of IL-6 and the establishment of planar polarity involved in neural tube closure.
Conclusions Our meta-analysis of this transcriptomic data provides a powerful approach to identify sex differences in NAFLD, when comparing NAFL and NASH. We detected relevant biological functions and molecular terms that were affected differently between premenopausal women and men. Changes in the immune responsiveness between men and women with NAFLD suggested that women have a more immune tolerant milieu while men have an impaired liver regenerative response.
Synopsis Progression from NAFL to NASH differently affects cellular functions in women and men. Here we systematically reviewed publicly available transcriptomic data and then performed a meta-analysis to find these affected functions. Thus, we identified 13 biological functions implicated in the progression of NAFLD that were differentially affected by sex.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by grants from GV/2020/186 and ISCIII PT17/0009/0015 FEDER. Marina Berenguer has a received a grant from the IISCIII (PI19/01360).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This paper has used data from previously published studies and is therefore exempt from further ethics committee approvals.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support statement: This research was supported by grants from GV/2020/186 and ISCIII PT17/0009/0015 FEDER. Marina Berenguer has a received a grant from the IISCIII (PI19/01360).
Conflict of interest statement: The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
Transcript profiling: In this work we have used transcriptomic data available in the Gene Expression Omnibus database with accession number: GSE48452, GSE61260, GSE66676, GSE83452, GSE89632, GSE126848 and GSE130970
Writing Assistance: María Ledrán. Supported by the Bioinformatics and Biostatistics Unit of Principe Felipe Research Center.
Improved the results and discussion sections. Added the web tool for displaying results.
Data Availability
This work uses data published in previous studies, which is available in the Gene Expression Omnibus repository.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48452
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61260
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66676
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83452
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89632
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126848
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130970
List of Abbreviations
- BH
- Benjamini & Hochberg p-value adjusting method
- GEO
- Gene Expression Omnibus
- GO
- Gene Ontology
- GSA
- Gene set analysis
- KEGG
- Kyoto Encyclopaedia of Genes and Genomes
- LOR
- Log-odds ratio
- NAFLD
- Non-alcoholic fatty liver disease
- NAFL
- Non-alcoholic steatosis
- NASH
- Non-alcoholic steatohepatitis
- PCA
- Principal component analysis
- PPA
- Pathway activity analysis
- PRISMA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- RMA
- Robust Multichip Average